GET DAILY SIGNALSBiodesix (BDSX) Q3 2025 Earnings: Revenue Rises 20% with Margin Gains and Raised Guidance
Key Takeaways
- Biodesix reported third-quarter 2025 revenue of $21.8 million, up 20% year over year and ahead of the roughly $21.0 million consensus estimate.
- Gross margin expanded to 81%, a 400-basis-point improvement from 77% in the prior-year period, driven by cost reductions per test.
- The net loss narrowed to $8.7 million, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) improved to a loss of $4.6 million, an 18% gain versus a year ago.
- Management raised full-year 2025 revenue guidance to $84 million–$86 million and said it expects adjusted EBITDA to turn positive in the fourth quarter.
- The company ended the quarter with $16.6 million in cash and cash equivalents, with development services revenue nearly doubling to $1.9 million.
Why These Results Matter
BDSX is a diagnostic solutions company focused on lung disease, generating revenue primarily from blood-based lung cancer tests and services for biopharmaceutical partners. Its latest quarterly earnings matter because they show whether the company can keep expanding test volumes while tightening losses on its path toward profitability. Recent quarters have featured accelerating revenue growth, margin gains, and a deliberate expansion of its sales force. I am watching closely whether that commercial momentum, combined with a recovery in Medicare Advantage claim payments and a fast-growing development services business, can translate into sustainable cash-flow improvement. The results also offer a signal on broader demand for precision lung diagnostics in an evolving reimbursement and regulatory environment.
The Quarter’s Reported Results
For the third quarter ended September 30, 2025, BDSX reported total revenue of $21.8 million, a 20% increase from $18.2 million a year earlier and above the consensus estimate of roughly $21.0 million. Lung diagnostic testing revenue rose 16% to $19.8 million, supported by approximately 15,700 tests (up 13% year over year) and a higher average revenue per test. Development services revenue surged 97% to $1.9 million, and the company exited the quarter with $12.9 million under contract but not yet recognized, an all-time high.
Gross margin improved to 81%, up 400 basis points from 77% in the prior-year quarter. The net loss narrowed to $8.7 million, a 15% improvement, and adjusted EBITDA improved 18% to a loss of $4.6 million. On a per-share basis, the company reported a loss of $1.16, better than the consensus estimate of a $1.60 loss. Management also raised full-year 2025 revenue guidance to $84 million–$86 million and guided to adjusted EBITDA positivity in the fourth quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
The market responded favorably to the report, with the stock advancing sharply in the session following the November 3, 2025 release. The revenue beat, expanded gross margin, raised guidance, and the outlook for fourth-quarter adjusted EBITDA positivity were key drivers of the positive reaction. Investor sentiment also appeared supported by management's commentary that a large Medicare Advantage plan resumed paying current claims and that primary care test ordering continues to grow. It is worth noting that the company completed a 1-for-20 reverse stock split in September 2025 to regain compliance with Nasdaq listing requirements, which remains part of the broader context for the share price. Despite the upbeat tone, lingering concerns around cash reserves and ongoing net losses temper the narrative.
Forward Outlook and Key Factors to Monitor
Looking ahead, the central question is whether BDSX can convert its commercial momentum into adjusted EBITDA positivity in the fourth quarter and sustain that trajectory into 2026. The company has guided to 93–97 sales representatives in the field during the fourth quarter and expects gross margins to remain near 80%. Continued growth in lung diagnostic test volumes and average revenue per test will be critical to hitting the raised full-year revenue range of $84 million–$86 million.
Investors should also monitor the development services pipeline. The company's $12.9 million in contracted-but-unrecognized revenue represents a growing, higher-margin opportunity, though the timing of recognition can vary. Reimbursement dynamics remain important as well; management is still working to collect on older Medicare Advantage claims that were not previously booked as revenue, and any back-payments could provide a tailwind.
Finally, watch cash and liquidity. Biodesix ended the quarter with $16.6 million in unrestricted cash and has relied on debt and its at-the-market equity program to fund operations. The company's ability to narrow its losses while investing in sales expansion and clinical studies will shape both its balance sheet and investor confidence in the quarters ahead. From what I see, this remains an important area to track.
My Take on Using AI Tools for Research
In my own analysis, I frequently rely on Tickeron’s AI Screener to quickly compare names like BDSX against industry peers on fundamentals, momentum, and technical signals. It helps surface comparable opportunities and monitor shifting trends across the diagnostics space without manual effort. This approach keeps my process efficient while highlighting potential trade ideas in healthcare.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for BDSX turns negative, indicating new downward trend
BDSX saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 80 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for BDSX turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 43 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
BDSX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BDSX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BDSX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BDSX's RSI Oscillator exited the oversold zone, 30 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +12.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDSX advanced for three days, in 202 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
BDSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. BDSX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.893) is normal, around the industry mean (66.084). P/E Ratio (-6.400) is within average values for comparable stocks, (2.723). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.463) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement